SCHEMBL13665381

SCHEMBL13665381

N=COc1ccc(NC(=O)c2cccs2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.49
NPC1 O15118 7/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
TDP1 Q9NUW8 1/20 0.49
HDAC1 Q13547 1/20 0.45
SMN1; SMN2 Q16637 6/20 0.44
ALDH1A1 P00352 5/20 0.44
TP53 P04637 4/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 2/20 0.44
CASP1 P29466 1/20 0.44
ATM Q13315 1/20 0.44
LMNA P02545 3/20 0.43
MAPT P10636 1/20 0.43
GFER P55789 1/20 0.43
HTT P42858 1/20 0.43
MAPK1 P28482 1/20 0.43
APLNR P35414 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13665387 0.75 ALOX15 (0.58) RAB9ANPC1MEN1KMT2ATDP1
SCHEMBL14394393 0.72 NPC1 (0.69) RAB9ANPC1MEN1KMT2ATDP1
SCHEMBL13665379 0.71 GAA (0.37) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL5991688 0.66 RAB9A (0.80) RAB9ANPC1MEN1KMT2ATDP1
SCHEMBL7530819 0.65 RAB9A (0.62) RAB9ANPC1MEN1KMT2ATDP1
SCHEMBL1858111 0.65 RAB9A (0.78) RAB9ANPC1MEN1KMT2ATDP1
SCHEMBL1884686 0.65
SCHEMBL8402365 0.65 HDAC1 (0.75) RAB9ANPC1MEN1KMT2ATDP1
SCHEMBL13665339 0.65
SCHEMBL13665361 0.65 LMNA (0.44) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 RAB9A 2711/4885NPC1 2575/4885MEN1 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.